Merck & Co. Inc. stock underperforms Monday when compared to competitors
Shares of Merck & Co. Inc. MRK shed 1.31% to $115.63 Monday, on what proved to be an all-around great trading session for the ...
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., ...
Zacks.com on MSN4d
Merck Loses Around $32B in 3 Months: Time to Sell the Stock?
Merck’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value. Merck ...
Merck wins first FDA approval for Keytruda as a treatment for mesothelioma
Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a ...
Where Will Merck Stock Be in 5 Years?
Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...
Merck & Co Unusual Options Activity For September 23
Benzinga is an innovative financial news outlet that has become the first choice for brokerages given its easy-to-integrate API suite and easy-to-consume content. Benzinga provides timely, actionable ...
STAT11d
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
STAT's podcast The Readout Loud discusses Summit's cancer immunotherapy, the company's co-CEO, Moderna's spending cuts and ...
Daiichi Sankyo-Merck's 'guided-missile' cancer drug meets main goal in late-stage trial
Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...
Merck & Co. Inc. stock outperforms competitors despite losses on the day
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
FierceBiotech7d
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...
Merck’s Top-Seller Cements Status in Hard-to-Treat Breast Cancer
Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for the first-line treatment of adult ...